natgillin/translations-raw huggingface dataset:
• Unscrew the needle and dispose of it carefully in accordance with local guidelines. 
• Iglo odvijte in jo pazljivo zavrzite v skladu z lokalnimi predpisi.
SUSTAIN 1 - Monotherapy 
SUSTAIN 1 - Monoterapija
Treat your pen with care. 
S peresnikom ravnajte previdno.
Semaglutide has no or negligible influence on the ability to drive or use machines. 
Semaglutid nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Therefore, semaglutide should not be used during pregnancy. 
Zato se semaglutida med nosečnostjo ne sme uporabljati.
To help you remember to inject this medicine once a week only, it is recommended to note the chosen weekday (e.g. Wednesday) on the carton and to write the date on the carton every time you have injected it. 
Da si boste lažje zapomnili injiciranje tega zdravila le enkrat na teden, je priporočljivo, da si izbrani dan (npr. sreda) zapišete na škatlo; poleg tega je priporočljivo tudi, da na škatlo vedno zapišete datum,
Semaglutide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. 
Semaglutida se ne sme uporabljati pri bolnikih s sladkorno boleznijo tipa 1 ali za zdravljenje diabetične ketoacidoze.
GLP-1 receptors are also expressed in the heart, vasculature, immune system and kidneys. 
Receptorji GLP-1 so izraženi tudi v srcu, ožilju, imunskem sistemu in ledvicah.
If you do not check the flow before your first injection with each new pen, you may not get the prescribed dose and the intended effect of Ozempic. 
Če pred prvim injiciranjem z vsakim novim injekcijskim peresnikom ne preverite pretoka, morda ne boste dobili predpisanega odmerka in želeni učinek zdravila Ozempic ne bo dosežen.
As a risk to a breast-fed child cannot be excluded, semaglutide should not be used during breast-feeding. 
Ker ni mogoče izključiti tveganja za dojenega otroka, se semaglutida med obdobjem dojenja ne sme uporabljati.
GLP--1 is a physiological hormone that has multiple actions in glucose and appetite regulation, and in the cardiovascular system. 
GLP-1 je fiziološki hormon, ki opravlja več nalog v regulaciji glukoze in apetita ter v srčno-žilnem sistemu.
It helps your body reduce your blood sugar level only when blood sugar is too high and can help prevent heart disease. 
To zdravilo telesu pomaga zmanjšati koncentracijo krvnega sladkorja, le kadar je krvni sladkor previsok, in lahko pomaga preprečiti bolezni srca.
Cardiac electrophysiology (QTc) 
Srčna elektrofiziologija (QTc)
In general, these reactions were mild or moderate in severity and of short duration. 
Na splošno so bili ti učinki blagi ali zmerni in kratkotrajni.
The events led to treatment discontinuation in 3.9% and 5% of patients. 
Prenehanje zdravljenja so omenjeni neželeni učinki povzročili pri 3,9 % oz. 5 % bolnikov.
This was observed in insulin-treated patients with known diabetic retinopathy. 
To je bilo opaženo pri bolnikih, zdravljenih z insulinom, ki so imeli znano diabetično retinopatijo.
Five trials (SUSTAIN 1-5) had the glycaemic efficacy assessment as the primary objective, while one trial (SUSTAIN 6) had cardiovascular outcome as the primary objective. 
V petih preskušanjih (SUSTAIN 1-5) je bil primarni cilj ocena glikemične učinkovitosti, v enem preskušanju (SUSTAIN 6) pa je bil primarni cilj srčno-žilni izid.
How to handle a blocked needle 
Kako ravnati z zamašeno iglo?
Make sure you select the full dose you need. 
Poskrbite, da izberete celoten predpisani odmerek.
There were 61% males, the mean age was 65 years and mean BMI was 33 kg/m2. 
61 % je bilo moških, povprečna starost je bila 65 let in povprečni ITM je bil 33 kg/m2.
Cmax was not affected for any of the compounds. 
Cmax se ni spremenila za nobeno od učinkovin.
Due to species differences in yolk sac anatomy and function, and due to lack of GLP-1 receptor expression in the yolk sac of non-human primates, this mechanism is considered unlikely to be of relevance to humans. 
Zaradi razlik v anatomiji in funkciji rumenjakove vrečke med živalskimi vrstami in zaradi odsotnosti izraženosti receptorjev GLP-1 v rumenjakovi vrečki ne-človeških primatov, velja, da ta mehanizem za človeka verjetno ni pomemben.
The effect of semaglutide on cardiac repolarization was tested in a thorough QTc trial. 
Vpliv semaglutida na repolarizacijo srca so preverili s podrobnim preskušanjem QTc.
After one year of treatment, a weight loss of ≥5% and ≥10% was achieved for more subjects with 
Telesna masa Po enem letu zdravljenja je zmanjšanje telesne mase za ≥ 5 % in ≥ 10 % doseglo več bolnikov z
This was also shown for subjects with type 2 diabetes and with renal impairment based on data from phase 3a studies, although the experience in patients with end-stage renal disease was limited. 
Prav tako je bilo to dokazano pri bolnikih s sladkorno boleznijo tipa 2 in okvaro ledvic na podlagi podatkov študij faze 3a, toda izkušenj pri bolnikih s končno odpovedjo ledvic je malo.
• increase of pancreatic enzymes (such as lipase and amylase). 
• zvišanje koncentracije encimov trebušne slinavke (npr. lipaze in amilaze)
What Ozempic is and what it is used for 
Kaj je zdravilo Ozempic in za kaj ga uporabljamo
Ozempic is to be administered once weekly at any time of the day, with or without meals. 
Zdravilo Ozempic je treba injicirati enkrat na teden, ob kateri koli uri, ne glede na obroke.
Frequency based on cardiovascular outcomes trial. 
Pogostnost na podlagi preskušanja srčno-žilnih izidov.
Low blood sugar is more likely to happen if you also take a sulfonylurea or insulin. 
Prenizek krvni sladkor je bolj verjeten, če uporabljate tudi sulfonilsečnino ali insulin.
With an elimination half-life of approximately 1 week, semaglutide will be present in the circulation for about 5 weeks after the last dose. 
Ker je eliminacijski razpolovni čas približno 1 teden, je semaglutid v obtoku prisoten še približno 5 tednov po zadnjem odmerku.
Get help from a person with good eyesight who is trained to use the Ozempic pre-filled pen. 
Pomaga naj vam oseba, ki dobro vidi in je usposobljena za uporabo napolnjenega injekcijskega peresnika Ozempic.
EXP Discard pen 6 weeks after first use. 
EXP Injekcijski peresnik zavrzite 6 tednov po prvi uporabi.
If no drop appears, you will not inject any medicine even though the dose counter may move. 
Če se kapljica ne pojavi, zdravila ne boste injicirali, tudi če se števec odmerka premakne.
You will need it after the injection, to safely remove the needle from the pen. 
Potrebovali ga boste po injiciranju, da boste iglo varno sneli s peresnika.
If you have diabetic eye disease and are using insulin, this medicine may lead to a worsening of your vision, and this may require treatment. 
Diabetična očesna bolezen (retinopatija) Če imate diabetično očesno bolezen in uporabljate insulin, lahko to zdravilo povzroči poslabšanje vašega vida in zahteva dodatno zdravljenje.
• on its own - if your blood sugar is not controlled well enough by diet and exercise alone, and you cannot use metformin (another diabetes medicine) or 
• sámo, če krvni sladkor z dieto in s telesno vadbo ni dovolj urejen in ne morete jemati metformina (drugega zdravila za zdravljenje sladkorne bolezni), ali
In addition, semaglutide reduces the preference for high fat foods. 
Poleg tega semaglutid zmanjša nagnjenost k uživanju zelo mastne hrane.
• less appetite 
• slabši apetit
• Before you use the pen for the first time, your doctor or nurse will show you how to use it. 
• Preden prvič uporabite injekcijski peresnik, vam bo zdravnik ali medicinska sestra pokazal/a, kako ga uporabljate.
3 ml (4 doses) 
3 ml (4 odmerki)
For diastolic blood pressure, there were no significant differences between semaglutide and comparators. 
Kar zadeva diastolični krvni tlak, med semaglutidom in primerjalnimi zdravili ni bilo značilnih razlik.
They can include: cold sweat, cool pale skin, headache, fast heartbeat, feeling sick (nausea) or very hungry, changes in vision, feeling sleepy or weak, feeling nervous, anxious or confused, difficulty concentrating or shaking. 
Obsegajo lahko hladen znoj, hladno bledo kožo, glavobol, hiter srčni utrip, slabost (navzeo) ali hudo lakoto, spremembe vida, občutek zaspanosti ali šibkosti, živčnost, tesnobo ali zmedenost, težave z zbranostjo ali tresenje.
The glucose and appetite effects are specifically mediated via GLP-1 receptors in the pancreas and the brain. 
Učinki na glukozo in apetit potekajo specifično preko receptorjev GLP-1 v trebušni slinavki in možganih.
In lactating rats, semaglutide was excreted in milk. 
Pri doječih podganah se je semaglutid izločal v mleko.
The effect of semaglutide on fertility in humans is unknown. 
Vpliv semaglutida na plodnost pri človeku ni znan.
• Check the name and coloured label of your pen, to make sure that it contains Ozempic. 
• Preverite ime in barvno nalepko injekcijskega peresnika in se tako prepričajte, da vsebuje zdravilo Ozempic.
This will help your doctor decide if the dose of the sulfonylurea or insulin needs to be changed to reduce the risk of low blood sugar. 
To mu bo pomagalo pri presoji, ali je treba odmerek sulfonilsečnine ali insulina spremeniti, da bi zmanjšali tveganje za prenizek krvni sladkor.
Do not use this medicine if you notice that the solution is not clear and colourless or almost colourless. 
Tega zdravila ne uporabite, če opazite, da raztopina ni bistra in brezbarvna ali skoraj brezbarvna.
If blood appears at the injection site, press lightly. 
Če se na mestu injiciranja pojavi kri, nanj rahlo pritisnite.
OTHER SPECIAL WARNINGS, IF NECESSARY Do not store the pen with a needle attached. 
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA Ne shranjujte injekcijskega peresnika z nameščeno iglo.
If more than 5 days have passed, the missed dose should be skipped, and the next dose should be administered on the regularly scheduled day. 
Če je od izpuščenega odmerka minilo že več kot 5 dni, je treba izpuščeni odmerek preskočiti in naslednji odmerek injicirati na redni dan po urniku.
*human glucagon-like peptide-1 (GLP-1) analogue produced in Saccharomyces cerevisiae cells by recombinant DNA technology. 
*Analog humanega glukagonu podobnega peptida-1 (GLP-1 - glucagon-like peptide-1), pridobljen iz Saccharomyces cerevisiae s tehnologijo rekombinantne DNA.
• complications of diabetic eye disease (retinopathy) - you should inform your doctor if you experience eye problems, such as changes in vision, during treatment with this medicine. 
• zapleti diabetične očesne bolezni (retinopatije); obvestite zdravnika, če med zdravljenjem s tem zdravilom opazite težave z očmi, na primer spremembe vida
Approximately 3% of the dose was excreted as intact semaglutide via urine. 
Približno 3 % odmerka se je izločilo v urinu kot nespremenjeni semaglutid.
The most frequently reported adverse reactions in clinical trials were gastrointestinal disorders, including nausea (very common), diarrhoea (very common) and vomiting (common). 
Najpogosteje opisani neželeni učinki v kliničnih preskušanjih so bile prebavne motnje, vključno z navzeo (zelo pogosto), drisko (zelo pogosto) in bruhanjem (pogosto).
The trial population was distributed by age as: 1,598 patients (48.5%) ≥65 years, 321 (9.7%) ≥75 years, and 20 (0.6%) ≥85 years. 
Starostna porazdelitev populacije v preskušanju je bila naslednja: 1.598 bolnikov (48,5 %) starih ≥ 65 let, 321 (9,7 %) bolnikov starih ≥ 75 let in 20 (0,6 %) bolnikov starih ≥ 85 let.
Tell your doctor if you have diabetic eye disease or if you experience eye problems during treatment with this medicine. 
Zdravnika morate obvestiti, če imate diabetično očesno bolezen, ali če se vam med zdravljenjem s tem zdravilom pojavijo težave z vidom.
Ozempic is used: 
Zdravilo Ozempic se uporablja:
If you do that, you might not get the intended effect of this medicine. 
Če to storite, morda ne boste deležni želenega učinka tega zdravila.
Do not attach a new needle to your pen until you are ready to take your injection. 
Na injekcijski peresnik ne pritrjujte nove igle, dokler niste pripravljeni na injiciranje zdravila.
Therapeutic experience in patients ≥75 years of age is limited (see section 5.2). 
Izkušnje z zdravljenjem bolnikov, starih 75 let ali več, je malo (glejte poglavje 5.2).
Frequent blood testing to determine the ability of your blood to clot may be required. 
Morda bo potrebno opraviti več preiskav krvi, da se oceni sposobnost vaše krvi za tvorjenje krvnega strdka.
In a study with a single subcutaneous dose of radiolabelled semaglutide, it was found that the primary excretion routes of semaglutide-related material were via urine and faeces; approximately 2/3 of semaglutide-related material were excreted in urine and approximately 1/3 in faeces. 
V študiji enkratnega subkutanega odmerka radioaktivno označenega semaglutida so ugotovili, da sta primarni poti izločanja semaglutidu podobnih spojin urin in blato; približno 2/3 teh spojin sta se izločili v urinu in približno 1/3 v blatu.
Gender, race (White, Black or African-American, Asian) and ethnicity (Hispanic or Latino, nonHispanic or -Latino) had no effect on the pharmacokinetics of semaglutide. 
Spol, rasa in etnično poreklo Spol, rasa (bela rasa, črna rasa, Azijci) in etnično poreklo (latinskoameriško poreklo v primerjavi z ne latinskoameriškim poreklom) niso vplivali na farmakokinetiko semaglutida.
Intent-to-Treat (ITT) Population (N) 
Populacija z namenom zdravljenja (ITT - intent-to-treat) (N)
What you need to know before you use Ozempic Do not use Ozempic: 
Kaj morate vedeti, preden boste uporabili zdravilo Ozempic Ne uporabljajte zdravila Ozempic:
All pharmacodynamic evaluations were performed after 12 weeks of treatment (including dose escalation) at steady state with semaglutide 1 mg once weekly. 
Vse farmakodinamične ocene so opravili po 12 tednih zdravljenja (vključno s povečanjem odmerka) v stanju dinamičnega ravnovesja z 1 mg semaglutida enkrat na teden.
Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy, but other mechanisms cannot be excluded. 
Prehodno poslabšanje diabetične retinopatije povezujejo s hitrim izboljšanjem urejenosti glikemije, vendar drugih vzrokov ni mogoče izključiti.
In foetuses, major skeletal and visceral malformations were observed, including effects on long bones, ribs, vertebrae, tail, blood vessels and brain ventricles. 
Pri plodovih so opažali večje skeletne in visceralne malformacije, vključno z učinki na dolge kosti, rebra, vretenca, rep, žile in možganske prekate.
Consistent with the potentially immunogenic properties of medicinal products containing proteins or peptides, patients may develop antibodies following treatment with semaglutide. 
Skladno z možnimi imunogenimi lastnostmi zdravil, v katerih so beljakovine ali peptidi, se lahko po zdravljenju s semaglutidom pri bolnikih pojavijo protitelesa.
The frequencies of the adverse reactions are based on a pool of the phase 3a trials excluding the cardiovascular outcomes trial (see text below the table for additional details). 
Pogostnosti neželenih učinkov temeljijo na pojavnosti v preskušanjih faze 3a, izključujoč preskušanje srčno-žilnih izidov (za dodatne podrobnosti glejte besedilo pod preglednico).
The rodent C-cell tumours are caused by a non-genotoxic, specific GLP-1 receptor mediated mechanism to which rodents are particularly sensitive. 
Tumorje parafolikularnih celic pri glodalcih povzroča negenotoksičen, specifičen mehanizem preko receptorjev GLP-1, za katerega so glodalci posebno občutljivi.
Steady state exposure was achieved following 4-5 weeks of once weekly administration. 
Izpostavljenost v stanju dinamičnega ravnovesja je bila dosežena po 4 do 5 tednih injiciranja enkrat na teden.
The hazard ratio [95% CI] for time to nephropathy (new onset of persistent macroalbuminuria, persistent doubling of serum creatinine, need for continuous renal replacement therapy and death due to renal disease) was 0.64 [0.46; 0.88] driven by new onset of persistent macroalbuminuria. 
Razmerje ogroženosti [95 % IZ] za čas do nefropatije (novonastala perzistentna makroalbuminurija, perzistentna podvojitev vrednosti serumskega kreatinina, potreba po stalnem nadomestnem ledvičnem zdravljenju in smrt zaradi bolezni ledvic) je bilo 0,64 [0,46; 0,88]; glavni razlog je bila novonastala perzistentna makroalbuminurija.
• Warfarin or other similar medicines taken by mouth to reduce blood clotting (oral anti coagulants). 
• varfarin ali druga podobna peroralna zdravila proti strjevanju krvi (peroralne antikoagulante).
Always watch the dose counter to know how many mg you inject. 
Vedno glejte števec odmerka, da boste vedeli, koliko miligramov injicirate.
Ozempic should not be used if it has been frozen. 
Zdravila Ozempic se ne sme uporabiti, če je bilo zamrznjeno.
Clear and colourless or almost colourless, isotonic solution; pH=7.4. 
Bistra, brezbarvna ali skoraj brezbarvna izotonična raztopina s pH 7,4.
In-use shelf life: 6 weeks. 
Po prvi uporabi: 6 tednov.
The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase. 
Mehanizem zniževanja glukoze v krvi vključuje tudi manjšo upočasnitev praznjenja želodca v zgodnji postprandialni fazi.
Beta-cell function and insulin secretion 
Delovanje celic beta in izločanje insulina
For use by one person only. 
Izključno za uporabo pri enem samem bolniku.
Your doctor may ask you to test your blood sugar levels. 
Zdravnik vam bo morda naročil, da si merite koncentracijo krvnega sladkorja.
The efficacy and safety of Ozempic 0.5 mg and 1 mg once weekly were evaluated in six randomised controlled phase 3a trials that included 7,215 patients with type 2 diabetes mellitus (4,107 treated with semaglutide). 
Učinkovitost in varnost zdravila Ozempic 0,5 mg in 1 mg enkrat na teden so ocenili v šestih randomiziranih kontroliranih preskušanjih faze 3a, ki so zajela 7.215 bolnikov s sladkorno boleznijo tipa 2 (4.107 zdravljenih s semaglutidom).
Both improvement of glycaemic control and reduction of cardiovascular morbidity and mortality are an integral part of the treatment of type 2 diabetes. 
Izboljšanje uravnavanja glikemije in zmanjšanje obolevnosti in umrljivosti zaradi srčno-žilnih dogodkov sta neločljiva sestavna dela zdravljenja sladkorne bolezni tipa 2.
If there is still no drop, change the needle and repeat step 2 ‘Check the flow' once more. 
Če se kapljica še vedno ne pojavi, zamenjajte injekcijsko iglo in še enkrat ponovite korake pod točko 2, "Preverjanje pretoka".
The enzyme neutral endopeptidase (NEP) is expected to be involved in the metabolism of semaglutide. 
Domneva se, da je v presnovo semaglutida vključen encim nevtralna endopeptidaza (NEP).
Select your dose 
Izberite odmerek
• You can keep the pen for 6 weeks when stored at a temperature below 30°C or in a refrigerator 
• Injekcijski peresnik lahko shranjujete 6 tednov pri temperaturi do 30 °C ali v hladilniku (2 °C
These other medicines may include: oral antidiabetics (such as metformin, thiazolidinediones, sulfonylureas) or insulin. 
Med temi zdravili so lahko peroralni antidiabetiki (npr. metformin, tiazolidindioni, sulfonilsečnine) ali insulin.
• fast pulse 
• hiter srčni utrip
• Do not inject Ozempic which has been frozen. 
• Ne injicirajte zdravila Ozempic, ki je bilo zmrznjeno.
Semaglutide doses of 0.5 mg and 1 mg provide adequate systemic exposure over a body weight range of 40-198 kg. 
Odmerka semaglutida 0,5 mg in 1 mg zagotovita ustrezno sistemsko izpostavljenost v razponu telesne mase od 40 do 198 kg.
For further information on administration, see section 6.6. 
Za dodatne informacije o apliciranju zdravila glejte poglavje 6.6.
1.5 ml (4 doses) 
1,5 ml (4 odmerki)
• The active substance is semaglutide. 
• Učinkovina je semaglutid.
When Ozempic is added to existing metformin and/or thiazolidinedione therapy, the current dose of metformin and/or thiazolidinedione can be continued unchanged. 
Če je zdravilo Ozempic dodano obstoječemu zdravljenju z metforminom in/ali tiazolidindioni, je mogoče metformin in/ali tiazolidindione še naprej uporabljati v nespremenjenem odmerku.
During treatment with this medicine, you may feel sick (nausea) or be sick (vomiting), or have diarrhoea. 
Med zdravljenjem s tem zdravilom se vam lahko pojavi slabost (navzea), lahko bruhate ali imate drisko.
• Always keep your pen and needles out of the sight and reach of others, especially children. 
• Injekcijski peresnik in igle vedno shranjujte nedosegljive drugim, zlasti otrokom.
However, a direct effect of semaglutide on the foetus cannot be excluded. 
Neposrednega učinka semaglutida na plod kljub temu ni mogoče izključiti.
Other medicines and Ozempic 
Druga zdravila in zdravilo Ozempic
If the paper tab is broken, do not use the needle, as sterility is not guaranteed. 
Če je papirna nalepka poškodovana ali pretrgana, injekcijske igle ne uporabite, ker njena sterilnost v tem primeru ni zagotovljena.
No other treatment-related tumours were observed. 
Drugih tumorjev, povezanih z zdravljenjem s tem zdravilom, niso opazili.
Compared to native GLP-1, semaglutide has a prolonged half-life of around 1 week making it suitable for once weekly subcutaneous administration. 
V primerjavi z naravnim GLP-1 ima semaglutid daljši razpolovni čas (približno 1 teden), zato je primeren za subkutano apliciranje enkrat na teden.
There is no experience in patients with congestive heart failure NYHA class IV and semaglutide is therefore not recommended in these patients. 
Izkušenj pri zdravljenju bolnikov s srčnim popuščanjem razreda IV po razvrstitvi New York Heart Association (NYHA) ni in zato uporaba semaglutida pri teh bolnikih ni priporočljiva.
Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. 
Semaglutid deluje kot agonist receptorja GLP-1 ter se selektivno veže in aktivira receptor GLP-1, ki je tarča naravnega GLP
1.5 ml or 3 ml glass cartridge (type I glass) closed at the one end with a rubber plunger (chlorobutyl) and at the other end with an aluminium cap with a laminated rubber sheet (bromobutyl/polyisoprene) inserted. 
1,5-ml ali 3-ml steklen vložek (steklo tipa I), na eni strani zaprt z gumijastim batom (klorobutil) in na drugi strani z aluminijastim pokrovčkom z vstavljeno plastjo laminirane gume (bromobutil/poliizopren).
A 2-year clinical trial investigated 3,297 patients with type 2 diabetes, with high cardiovascular risk, long duration of diabetes and poorly controlled blood glucose. 
V 2-letnem kliničnem preskušanju so preučili 3.297 bolnikov s sladkorno boleznijo tipa 2 z velikim srčno-žilnim tveganjem, dolgotrajno sladkorno boleznijo in slabo urejeno glikemijo.
Patients treated with semaglutide in combination with a sulfonylurea or insulin may have an increased risk of hypoglycaemia. 
Bolniki, ki prejemajo semaglutid skupaj s sulfonilsečnino ali insulinom, imajo lahko večje tveganje za hipoglikemijo.
If a dose is missed, it should be administered as soon as possible and within 5 days after the missed dose. 
V primeru izpuščenega odmerka je treba odmerek injicirati čim prej, znotraj 5 dni po izpuščenem odmerku.
• it is 5 days or less since you should have used Ozempic, use it as soon as you remember. 
• je od izpuščenega odmerka zdravila Ozempic minilo 5 dni ali manj, zdravilo uporabite takoj ko se spomnite.
If a drop still does not appear, dispose of the pen and use a new one. 
Če kapljice še vedno ni, injekcijski peresnik zavrzite in uporabite novega.
The total number of primary component MACE endpoints was 254, including 108 (6.6%) with semaglutide and 146 (8.9%) with placebo. 
Skupno število primarnih opazovanih dogodkov MACE je bilo 254, od teh 108 (6,6 %) med prejemniki semaglutida in 146 (8,9 %) med prejemniki placeba.
• Do not expose your pen to dust, dirt or liquid. 
• Injekcijskega peresnika ne izpostavljajte prahu, umazaniji ali tekočinam.
Your doctor may reduce your dose of these medicines before you start using this medicine. 
Zdravnik lahko pred uvedbo zdravljenja z zdravilom Ozempic odmerek teh zdravil zmanjša.